28/02/2017

FIDIA PHARMA GROUP EXPECTED TO BE A KEY PLAYER IN THE OPHTHALMIC SECTOR

The Company is finalizing the acquisition of Italian Sooft/Oox Group

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks.

Sooft/Oox is an Italian group active in the ophthalmic sector, with a product portfolio that includes several well-known brands, amongst them, Iridium e Blugel. The Group is positioned among the top four companies in this market segment, and is engaged in the development of products for all major eye diseases.

The acquisition of the Sooft/Oox Group will enable Fidia, who was active in the ophthalmology segment in previous years, to re-gain market share and strengthen its position in this area, offering products under various therapeutic categories, such as eye drops, nutraceuticals and medical devices.

Further updates and details will be provided as soon as the acquisition is executed.
 

The Group is positioned among the top four companies in this market segment, and is engaged in the development of products for all major eye diseases.

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Other product websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.